Galapagos NV (GLPG): Price and Financial Metrics


Galapagos NV (GLPG)

Today's Latest Price: $193.44 USD

3.31 (1.74%)

Updated Aug 13 5:20pm

Add GLPG to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 344 in Biotech

See all "A" rated Strong Buy stocks

GLPG Stock Summary

  • For GLPG, its debt to operating expenses ratio is greater than that reported by just 8.05% of US equities we're observing.
  • With a year-over-year growth in debt of 21,864.54%, Galapagos Nv's debt growth rate surpasses 99.53% of about US stocks.
  • Revenue growth over the past 12 months for Galapagos Nv comes in at 1,371.61%, a number that bests 99.28% of the US stocks we're tracking.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Galapagos Nv are TLC, GMAB, ERYP, NVEC, and HIMX.
  • Visit GLPG's SEC page to see the company's official filings. To visit the company's web site, go to www.glpg.com.
GLPG Daily Price Range
GLPG 52-Week Price Range

GLPG Stock Price Chart Technical Analysis Charts


GLPG Price/Volume Stats

Current price $193.44 52-week high $274.03
Prev. close $190.13 52-week low $112.00
Day low $191.47 Volume 71,269
Day high $195.74 Avg. volume 149,774
50-day MA $197.73 Dividend yield N/A
200-day MA $205.70 Market Cap 12.62B

Galapagos NV (GLPG) Company Bio


Galapagos NV is a clinical-stage biotechnology company specialized in the discovery and development of small molecule medicines in areas such as cystic fibrosis, inflammation, and other indications. The company was founded in 1999 and is Mechelen, Belgium.





GLPG Latest News Stream


Event/Time News Detail
Loading, please wait...

GLPG Latest Social Stream


Loading social stream, please wait...

View Full GLPG Social Stream

Latest GLPG News From Around the Web

Below are the latest news stories about Galapagos Nv that investors may wish to consider to help them evaluate GLPG as an investment opportunity.

GILEAD  AND  GALAPAGOS  ANNOUNCE  POSITIVE  EUROPEAN  CHMP  OPINION  FOR  JYSELECA®  (FILGOTINIB)  FOR  THE  TREATMENT  OF  ADULTS  WITH  MODERATE  TO  SEVERE  RHEUMATOID  ARTHRITIS

\-- Clinical Development Program of Filgotinib Demonstrated Durable Efficacy Balanced with a Consistent Safety Profile in Rheumatoid Arthritis Through 52 Weeks -- Foster City, Calif., and Mechelen, Belgium, July 24 2020, 14:10 CET; regulated information – Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos NV (Euronext & Nasdaq: GLPG) announced today the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Jyseleca® (filgotinib 200 mg and 100 mg tablets), an investigational, once-daily, oral, selective JAK1 inhibitor for the treatment of adults with moderate to severe rheumatoid arthritis (RA) who have responded inadequately or are intolerant to one or more disease modifying anti-rheumatic drugs (DMARDs). The ...

Yahoo | July 24, 2020

Gilead and Galapagos Announce Positive European CHMP Opinion for Jyseleca® (Filgotinib) for the Treatment of Adults With Moderate to Severe Rheumatoid Arthritis

Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos NV (Euronext & Nasdaq: GLPG) announced today the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Jyseleca® (filgotinib 200 mg and 100 mg tablets), an investigational, once-daily, oral, selective JAK1 inhibitor for the treatment of adults with moderate to severe rheumatoid arthritis (RA) who have responded inadequately or are intolerant to one or more disease modifying anti-rheumatic drugs (DMARDs). The CHMP positive opinion is a scientific recommendation to the European Commission to grant marketing authorization in Europe.

Yahoo | July 24, 2020

5 Greenblatt Magic Formula Biotech Stocks to Weather the Summer Coronavirus Storm

Stocks to consider as biotech company Novavax gets $1.6 billion in federal aid for Covie-19 vaccine Continue reading...

Yahoo | July 7, 2020

Better Buy: Vertex Pharmaceuticals vs. Galapagos

Is an industry leader in treating cystic fibrosis or a company with a potential miracle drug the better buy for investors?

Yahoo | July 2, 2020

Hedge Funds Are Warming Up To Galapagos NV (GLPG)

In this article we will take a look at whether hedge funds think Galapagos NV (NASDAQ:GLPG) is a good investment right now. We check hedge fund and billionaire investor sentiment before delving into hours of research. Hedge funds spend millions of dollars on Ivy League graduates, unconventional data

Yahoo Finance | June 26, 2020

Read More 'GLPG' Stories Here

GLPG Price Returns

1-mo 0.74%
3-mo -12.20%
6-mo -25.31%
1-year 14.06%
3-year 123.48%
5-year 217.84%
YTD -6.47%
2019 125.45%
2018 -2.15%
2017 46.07%
2016 2.08%
2015 239.71%

Continue Researching GLPG

Want to see what other sources are saying about Galapagos Nv's financials and stock price? Try the links below:

Galapagos Nv (GLPG) Stock Price | Nasdaq
Galapagos Nv (GLPG) Stock Quote, History and News - Yahoo Finance
Galapagos Nv (GLPG) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.8901 seconds.